Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

被引：9

作者：

Abou-Alfa, Ghassan K.

Cheng, Ann-Lii

Meyer, Tim

El-Khouelry, Anthony B.

Ikeda, Masafumi

Chun, Hoo Geun

Falvre, Sandrine J.

Furuse, Junji

Knox, Jennifer J.

Okusaka, Takuji

Ping, Jerry

Borgman-Hagey, Anne E.

Kelley, Robin Kate

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Royal Free Hosp, London NW3 2QG, England

[5] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA

[6] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan

[7] Catholic Univ, Seoul St Marys Hosp Korea, Seoul, South Korea

[8] Hop Beaujon, Clichy, France

[9] Kyorin Univ, Sch Med, Dept Med Oncol, Tokyo, Japan

[10] Princess Margaret Canc Ctr, Toronto, ON, Canada

[11] Natl Canc Ctr, Tokyo, Japan

[12] Exelixis Inc, San Francisco, CA USA

[13] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.tps4150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4150

引用

页数：1